Pfizer set for July FDA verdict on rare heart disease drugPfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after Share XPfizer set for July FDA verdict on rare heart disease drughttps://pharmaphorum.com/news/pfizer-set-for-july-fda-verdict-on-rare-heart-disease-drug/
Pfizer drug reduces mortality in patients with fatal heart diseasePfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase Share XPfizer drug reduces mortality in patients with fatal heart diseasehttps://pharmaphorum.com/news/tafamidis-reduces-mortality/
